Products - Lung cancer | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 170 products

Date | Title

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (TA1060)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 May 2025
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
1 May 2025
Published:
23 June 2015
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) (TA1058)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2025
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) (TA1047)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 March 2025
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2025
Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 February 2025
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 February 2025
Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)
Product type:
Guidance
Programme:
Health technology evaluation
Last updated:
10 February 2025
Published:
28 September 2023
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 February 2025
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2025
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA1021)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 December 2024
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1017)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 November 2024
Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA976)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 May 2024
Lung cancer: diagnosis and management (NG122)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
8 March 2024
Published:
28 March 2019
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 July 2023
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 July 2023
AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images (DG55)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
5 July 2023
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 June 2023
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) (TA884)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 May 2023
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2023
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy (TA850)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 December 2022
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA848)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 December 2022
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2022
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 August 2022
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2022
Thopaz+ portable digital system for managing chest drains (MTG37)
Product type:
Guidance
Programme:
Medical technologies guidance
Last updated:
6 June 2022
Published:
21 March 2018
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 May 2022
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 March 2022
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
23 February 2022
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 February 2022
Microwave ablation for primary or metastatic cancer in the lung (IPG716)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
2 February 2022
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 September 2021
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 June 2021
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 March 2021
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2021
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 October 2020
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 October 2020
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 August 2020
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
1 July 2020
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 June 2020
Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 May 2020
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 May 2020
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) (TA618)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2020
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 August 2019
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2019
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 July 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 May 2018
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2018
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
11 January 2017
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
10 August 2017
Published:
23 June 2010
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) (TA444)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 May 2017
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 March 2017
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 March 2017
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 December 2016
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2015
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2015
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (TA347)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 July 2015
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 April 2014
EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
14 August 2013
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours (TA265)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 October 2012
Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (TA258)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 June 2012
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2011
Percutaneous radiofrequency ablation for primary or secondary lung cancers (IPG372)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
15 December 2010
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (TA192)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 July 2010
Endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions (IPG337)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 March 2010
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2009
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 September 2009
Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) (TA148)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 June 2008
Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (IPG254)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 February 2008
Pemetrexed for the treatment of non-small-cell lung cancer (TA124)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 August 2007
Living-donor lung transplantation for end-stage lung disease (IPG170)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 May 2006
Cryotherapy for malignant endobronchial obstruction (IPG142)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2005
Photodynamic therapy for localised inoperable endobronchial cancer (IPG137)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2005
Photodynamic therapy for advanced bronchial carcinoma (IPG87)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 August 2004
Stent placement for vena caval obstruction (IPG79)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2004
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 October 2022
Artificial intelligence for analysing chest CT images (MIB243)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
5 January 2021
Archimedes for biopsy of suspected lung cancer (MIB211)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
11 June 2020
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
11 October 2019
Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
18 January 2018
HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
7 November 2017
ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
30 September 2015
Lung cancer in adults (QS17)
Product type:
Quality standard
Last updated:
13 December 2019
Published:
26 March 2012
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 June 2025
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
6 August 2025
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 August 2025
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 August 2025
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 September 2025
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 September 2025
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 September 2025
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 October 2025
Suspected Cancer: recognition and referral
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 April 2026
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177]
Status:
In development | In consultation
Programme:
Technology appraisal guidance
Consultation end date:
24 June 2025
Expected publication date:
TBC
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treatments for non-small-cell lung cancer [ID6234]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Perfusion-induced systemic hyperthermia for the treatment of advanced lung cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Percutaneous cryotherapy (PCT) for the therapy of primary lung cancer or metastatic lung cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Use of a glue or sealant to achieve lung volume reduction in emphysema and lung cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with pembrolizumab for maintenance treatment of advanced non-small-cell lung cancer after platinum-based chemotherapy with pembrolizumab [ID6345]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab in combination for untreated advanced non-squamous non-small-cell lung cancer [ID6443]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer PD [ID6526]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor TSID 11812
Status:
Topic selection
Programme:
Health technology evaluation
Expected publication date:
TBC
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Archimedes for biopsy of suspected lung cancer
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Signatera molecular residual disease assay (MT741)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy, (MT158)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Subcutaneous amivantamab for treating advanced non-small-cell lung cancer with EGFR mutations [TSID12011]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment [ID6467]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [TSID12115]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [TSID12104]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zongertinib for treating unresectable or metastatic non-small-cell lung cancer with activating HER2 (ERBB2) mutations [ID6573]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Catumaxomab for intraperitoneal treatment of malignant ascites in epithelial cellular adhesion molecule-positive cancers when further systemic anticancer treatment is unsuitable [ID12201]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC